Therapeutic Targeting of Complement C5a Receptors in HuntingtonÍs Disease
Therapeutic Targeting of Complement C5a Receptors in HuntingtonÍs Disease
批准号:
nhmrc : 1004455
负责人:
A/Pr John O'Sullivan
金额:
$31.23万
依托单位国家:
澳大利亚
项目类别:
Project Grants
财政年份:
2011
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2011-01-01 至 2013-12-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
HuntingtonÍs disease is a genetic neurodegenerative condition leading to progressive cognitive and motor deficits and eventual death. This research aims to explore the role of immune and inflammatory pathways in the progression of disease in patients suffering HuntingtonÍs disease, as well as in an animal model of this condition. By exploring these immune and inflammatory pathways, we aim to identify novel therapeutic targets to treat HuntingtonÍs disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A randomised placebo-controlled crossover trial of micronised resveratrol as a treatment for Friedreich ataxia
-
批准号:nhmrc : GNT1102207
-
项目类别:Project Grants
-
资助金额:$55.63万
-
财政年份:2016
-
负责人:A/Pr John O'Sullivan
-
依托单位:
A randomised placebo-controlled crossover trial of micronised resveratrol as a treatment for Friedreich ataxia
-
批准号:nhmrc : 1102207
-
项目类别:Project Grants
-
资助金额:$37.33万
-
财政年份:2016
-
负责人:A/Pr John O'Sullivan
-
依托单位:
Complement activation as a therapeutic target and clinical biomarker for Parkinson's disease
-
批准号:nhmrc : 1082250
-
项目类别:Project Grants
-
资助金额:$33.2万
-
财政年份:2015
-
负责人:A/Pr John O'Sullivan
-
依托单位:
国内基金
海外基金
Pre-targeting/Click反应介导的自体循环干细胞在心脏缺血损伤修复中的应用及机制研究
-
批准号:81873493
-
项目类别:面上项目
-
资助金额:57.0万元
-
批准年份:2018
-
负责人:沈德良
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位: